[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631601":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":27,"responsibleParty":45,"collaborators":49,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":18,"overallStatus":71,"whyStopped":18,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Liaquat University of Medical & Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neurofast® Supplementation","EXPERIMENTAL","Participants in this group will receive Neurofast® supplementation at a dose of 2 tablets per day (one tablet in the morning and one tablet in the evening) for a duration of 12 weeks, in addition to standard clinical care in a real-world setting.",[13],"Dietary Supplement: Neurofast® supplement",{"label":15,"type":16,"description":17,"interventionNames":18},"No Additional Treatment Control","NO_INTERVENTION","Participants in this group will not receive Neurofast® supplementation and will continue with standard clinical care without any additional intervention during the 12-week follow-up period.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Neurofast® supplement","Neurofast® is a nutraceutical formulation administered orally in tablet form and evaluated for its potential effects on psychological and cardiovascular parameters in individuals with the psycho-cardio phenotype.",[9],[26],"Neurofast®",[28],{"facility":29,"status":18,"city":30,"state":18,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"University of Rome Tor Vergata","Roma","00133","Italy","IT",{"type":35,"coordinates":36},"Point",[37,38],11.10642,44.99364,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":18,"phoneExt":18,"email":44},"Dr. Barbara Pala, MD","CONTACT","barbara.pala93@gmail.com",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Dr. Amjad Khan","Professor",[50],{"name":29,"class":6},"100631601","effect-of-neurofast-supplementation-on-anxiety-and-cardiovascular-outcomes-in-the-psycho-cardio-phenotype-adults-100631601",false,"NCT07502807","Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype Adults","Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype: A Prospective Real-World Interventional Observational Study","Inclusion Criteria:\n\n* Age 18-70 years (both sexes)\n* GAD-7 ≥ 5 and\u002For elevated CAQ score\n* PHQ-9 \\\u003C 20\n* Stable clinical status (either no cardiovascular disease or stable cardiovascular disease)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe chronic kidney disease (eGFR \\\u003C 50 ml\u002Fmin)\n* Severe hepatic impairment\n* Psychotic disorders, bipolar disorder, or acute major depression\n* Unstable psychiatric or pharmacological treatment (\\\u003C3 months)\n* Pregnancy or breastfeeding\n* Known allergy or intolerance to investigational treatments (if applicable)","ALL","18 Years","70 Years",{"count":62,"type":63},80,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study aims to evaluate anxiety and cardiovascular outcomes in individuals with the psycho-cardio phenotype, characterized by clinically relevant anxiety symptoms with or without established cardiovascular disease (CVD). The study will be conducted as a prospective, real-world interventional study over 12 weeks.\n\nParticipants will be allocated to either a group receiving Neurofast® supplementation (2 tablets per day) or a control group receiving no additional treatment. Psychological assessments will include the Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9), and Cardiac Anxiety Questionnaire (CAQ). Cardiovascular parameters, including heart rate, blood pressure, and electrocardiographic (ECG) measures, will also be evaluated.\n\nThe primary objective is to assess changes in anxiety symptoms and heart rate over 12 weeks. Secondary objectives include evaluation of depressive symptoms, cardiovascular parameters, and treatment adherence in a real-world clinical setting.",[69,70],"Anxiety","Cardiovascular Diseases","NOT_YET_RECRUITING","2026-03-27",{"date":74,"type":75},"2026-03-31","ACTUAL",{"date":77,"type":63},"2026-04-07",{"date":79,"type":63},"2027-01-31",{"name":5,"class":6},1]